•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.CapsoVision, Inc. (CV) Q3 2026 Earnings Call Transcript
What CapsoVision (CV) Said on Its Q3 Earnings Call
CapsoVision Reports Third Quarter 2026 Financial Results
CapsoVision (NASDAQ:CV) Share Price Crosses Above 200 Day Moving Average – What’s Next?
CapsoVision to Release Third Quarter 2026 Financial Results on November 12, 2026
CapsoVision Maps AI Capsule Push Into Colon, Pancreatic Cancer Screening
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
CapsoVision to Present at the 20th Annual LD Micro Main Event
New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease
Head to Head Survey: CapsoVision (NASDAQ:CV) vs. Brainsway (NASDAQ:BWAY)
CapsoVision (NASDAQ:CV) and NeuroPace (NASDAQ:NPCE) Critical Contrast
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress
CapsoVision gets FDA clearance for AI Highlights
CapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus®
CapsoVision (NASDAQ:CV) Major Shareholder Eliyahou Et Al Harari Purchases 1,757,469 Shares
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis
Critical Contrast: Zimmer Biomet (NYSE:ZBH) versus CapsoVision (NASDAQ:CV)
BlackRock Inc. Acquires New Shares in CapsoVision, Inc. $CV
CapsoVision to Participate in Upcoming Investor Conferences
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings